* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download molecular diagnosis in lgmd2a: mutation analysis or
Survey
Document related concepts
Gene therapy of the human retina wikipedia , lookup
Microevolution wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Gene nomenclature wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Frameshift mutation wikipedia , lookup
Protein moonlighting wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Transcript
PROTEIN AND MOLECULAR DIAGNOSIS IN LGMD2A A.C. Nascimbeni 1,2, L. Fulizio 1,2, M. Spinazzi 1,2, M. Fanin 1,2, C. Angelini 1,2 1 Department of Neurosciences, University of Padova; 2 Venetian Institute of Molecular Medicine, Padova. Tel. 049.7923202. Fax: 049.7923250. E-mail: [email protected] Limb girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene encoding for calpain-3, a muscle specific protease. The diagnosis of LGMD2A has recently shifted from molecular genetics towards biochemical assay of defective protein. However, an estimate of sensitivity and specificity of protein analysis remains to be established. Thus, we first correlated protein and molecular data in our large LGMD2A patient population. By a preliminary immunoblot screening of calpain-3 protein of 548 unclassified patients with various phenotypes (LGMD, myopathy, hyperCKemia), we selected 270 cases for CAPN3 gene mutation analysis: 83 had protein deficiency and 187 had normal expression. Mutation search was conducted using SSCP, DHPLC, ARMS-PCR and direct sequencing methods. We identified 70 LGMD2A mutant patients: 53 (76%) had variable degree of protein deficiency and 17 (24%) had normal calpain-3 amount. We calculated that the probability of having LGMD2A is very high when patients show a complete calpain-3 deficiency (84.4%) and progressively decreases with the amount of protein; this new data offers an important tool for genetic counseling when only protein data are available. A total of 47 different CAPN-3 gene mutations were detected, 22 of which are new. In our population, 86% of mutant alleles were concentrated in 7 exons (1,4,5,8,10,11,21). The prevalence of LGMD2A in North-Eastern Italy is 9.5 per million. In the Venetia district and in Friuli region it appears particularly frequent due to the recurrence of single mutations (a founder effect is likely). This study reports the largest collection of LGMD2A patients so far where both protein and gene mutation were obtained to draw genotype/protein/phenotype correlations and provide insights into critical protein domain.